Glucose Monohydrate — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

7 Recruiting

4 Completed trials

13 Sponsors

14 Countries

Phase III

Phase II/III

Phase II

Phase III: 6 Phase II/III: 2 Phase II: 3 Phase I/II: 1 Phase III/IV: 1 Phase IV: 1

Indications tested

Idiopathic pulmonary fibrosis 1 Small cell lung cancer extensive stage 1 Sepsis 1

Sponsors using this IMP

Mediar Therapeutics Inc. 2 Assistance Publique Hopitaux De Paris 1 Centre Hospitalier Et Universitaire De Limoges 1 Centre Hospitalier Universitaire De Nantes 1 Centre Hospitalier Universitaire Rouen 1 Curadel Surgical Innovations B.V. 1 Elliniko Institouto Meletis Tis Sipsis 1 Hospices Civils De Lyon 1 Lipigon Pharmaceuticals AB 1 Medical University Of Gdansk 1 Pharmacosmos A/S 1 Syddansk Universitet (University of Southern Denmark) 1

All trials

14 total

Evaluation of the efficacy of iloprost in the management of vaso-occlusive crises in adult patients with sickle cell: a multicentre, randomi… Pending

2025-522005-38-00 Phase III 1 country Centre Hospitalier Universitaire Rouen
Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc) Pending

2025-523288-39-00 Phase II 2 countries Mediar Therapeutics Inc.
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL Pending

2025-525058-20-00 Phase III 1 country Elliniko Institouto Meletis Tis Sipsis
Cerebral hemodynamic optimization by milrinone for the prevention of delayed cerebral ischemia in severe subarachnoid hemorrhage Recruiting

2024-513410-35-00 Phase III 1 country Centre Hospitalier Universitaire De Toulouse
Evaluation of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) Recruiting

2025-521278-32-00 Phase II 6 countries Mediar Therapeutics Inc.
CReep and maintenance flUid Salt ADministration rEduction in cRitically ill adultS - (CRUSADERS) Recruiting

2025-520744-14-00 Phase IV 1 country Universitair Ziekenhuis Antwerpen
DASSOH - Systematic use of DDAVP to prevent serum sodium overcorrection in severe hyponatremia : a multicenter open-label randomized control… Recruiting

2023-507254-32-00 Phase III 1 country Assistance Publique Hopitaux De Paris
A Phase 2/3 trial to investigate visualization of the ureters with nizaracianine triflutate, intravenous, in participants aged 18 years or o… Recruiting

2023-503241-63-00 Phase II/III 1 country Curadel Surgical Innovations B.V.; Curadel Surgical Innovations Inc.
A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To… Recruiting

2022-502357-34-00 Phase III 8 countries Pharmacosmos A/S
Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes) Recruiting

2024-515275-35-00 Phase II/III 1 country Hospices Civils De Lyon
Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome Ended

2024-515060-32-00 Phase III 1 country Medical University Of Gdansk
The headache-inducing effects of sildenafil in men and women with episodic migraine without aura. Ended

2024-512014-17-02 Phase I/II 1 country Syddansk Universitet (University of Southern Denmark)
A24110He in a placebo-controlled trial evaluating safety in subjects with elevated plasma triglycerides Ended

2023-509091-42-00 Phase II 1 country Lipigon Pharmaceuticals AB
Adjunctive DobutAmine in sePtic cardiomyopathy with Tissue hypoperfusion: a randomized controlled multi-center trial Ended

2024-517839-50-00 Phase III/IV 1 country Centre Hospitalier Et Universitaire De Limoges

Showing 1–14 of 14 trials

← All drugs A–Z